A protocol built for the cases standard treatment misses.
Physician-supervised, multi-mechanism. Designed for patients who have failed antibiotic eradication, who cannot tolerate the first-line regimens, or who want comprehensive mucosal recovery support alongside standard care — never as a replacement for it.
A research-grounded framework — not a Welyon product.
The following protocol architecture is based on published research into H. pylori's defense mechanisms. The ingredient categories below address five simultaneous mechanisms that standard antibiotic therapy does not specifically target. Welyon recommends discussing this framework with a physician before beginning.
Patients standard care has under-served.
- Patients who have failed eradication. First- or second-line antibiotic regimens completed; confirmatory testing still positive at 8 weeks. The protocol layers additional pharmacology and pathway pressure.
- Patients who cannot tolerate standard regimens — significant adverse reactions to clarithromycin, levofloxacin, metronidazole, or amoxicillin classes — and who therefore lack a clear guideline-concordant route.
- Patients seeking systematic mucosal recovery support alongside their standard antibiotic course — to address inflammation, barrier integrity, and downstream nutritional sequelae.
- Patients with confirmed positive testing and a clinical indication — a relevant condition from the eight-guide series, or a gastroenterology-recommended eradication indication.
Not a substitute for first-line therapy.
- Not a replacement for guideline-recommended antibiotic eradication in the standard first-line scenario. Standard care remains the appropriate first step.
- Not a wellness stack, supplement bundle, or do-it-yourself regimen. Engagement requires consultation with a licensed clinician through Welyon's network.
- Not a diagnostic step. The protocol is engaged only after a confirmed positive test and a clinical decision — not as an empirical trial in untested patients.
- Not appropriate where red-flag findings — active ulcer, gastric malignancy, severe atrophic gastritis — require specialist referral first.
Five mechanisms. One protocol.
The Foundation Protocol layers five distinct mechanistic targets, addressing the documented limitations of single-pathway antibiotic regimens — biofilm protection, efflux-pump resistance, and dormant persister sub-populations. Each mechanism is named below without ingredient detail; specific compositions are reviewed in the physician consultation, not on a public page.
Biofilm disruption
H. pylori forms protective biofilms on the gastric mucosa that shield organisms from antibiotic exposure. The protocol opens that matrix.
Multi-pathway antimicrobial pressure
Several independent antimicrobial mechanisms applied in parallel — reducing the probability that a single resistance pathway clears the organism's exposure.
Efflux pump inhibition
Bacterial efflux pumps are a documented mechanism of acquired antibiotic resistance. The protocol includes targeted efflux-pump inhibition to preserve the antimicrobial concentration at the organism.
Dormant population targeting
A subset of organisms enter a metabolically quiescent state — "persisters" — that standard antibiotic regimens do not fully clear. The protocol addresses this sub-population.
Mucosal repair
Eradication is one outcome; mucosal recovery is another. The protocol supports gastric barrier integrity, inflammation resolution, and the downstream nutritional pathways the literature has implicated.
What to look for when sourcing these ingredients.
No brand names are recommended here. When selecting products independently, look for the following — each criterion exists to keep the architecture clinically meaningful rather than nominally on-label.
-
i.
Standardised extracts at clinically studied dosesThe dose tested in the human literature, not a generic herbal weight. "Standardised to X% of active compound" on the label, matching what the underlying trials used.
-
ii.
Third-party GMP certificationNSF, USP, or equivalent third-party certification of Good Manufacturing Practices. Independent verification of identity, purity, and dose accuracy — not the manufacturer's self-claim.
-
iii.
Bioavailable forms confirmed in human trialsThe specific molecular form the trials used — not the cheaper analogue that shares a name. Bioavailability data on the form you're buying, not extrapolated from a related compound.
-
iv.
No fillers or proprietary blendsEvery active ingredient quantity printed on the label. "Proprietary blends" obscure the dose of each component; without that number, the published evidence is hard to apply to the bottle you actually hold.
Engaged through a physician — not bought as a kit.
The Foundation Protocol is not sold as a stand-alone product. It is engaged through consultation with a licensed clinician — independent of Welyon, contracted on a per-consultation basis — who reviews your history, test results, current medications, and any contraindications before any protocol is initiated.
The physicians are not Welyon employees. Their clinical decisions, including whether the protocol is appropriate at all for your specific case, are made independently. Their decision can be no.
A telehealth consultation pathway — US-licensed clinicians, secure video, asynchronous follow-up — is in late-stage build for launch in 2026. The waitlist below is the route to a confirmed appointment slot when the pathway opens; no charge to join.
Notified first when the pathway opens.
Email only. We'll write once when slots are released. No marketing sequence, no clinic-day calls, no partner sharing.
One email when the pathway opens. Unsubscribe in one click. No partner sharing.
Every participant contributes to the evidence base.
The Foundation Protocol is conducted under a pre-registered observational study protocol — pre-registered before enrolment opens, reviewed by an independent Institutional Review Board, with primary endpoints, secondary endpoints, and the analysis plan fixed in advance. Every participant is invited (not required) to contribute their de-identified outcomes to the dataset.
The intent is straightforward: generate the evidence base that the protocol's mechanism profile deserves. The pre-registered design means findings — favourable or unfavourable — are reported. Negative results do not get filed away.
- Registration ClinicalTrials.gov · registration ID forthcoming Pre-launch
- IRB Independent IRB · approval forthcoming Required · pre-enrolment
- Design Prospective observational · single-arm · longitudinal Pre-registered
- Primary endpoint Eradication confirmed by stool antigen at 8 weeks post-protocol Per ACG protocol
- Secondary endpoints Adverse-event profile · condition-specific markers · 6-month durability Pre-specified
- Participation Opt-in · de-identified · no cost to participate Informed consent
Who the protocol is not for.
Stated explicitly so the consultation conversation is shorter. Two situations where the protocol is not appropriate — or not yet appropriate — are listed below. A third clarification follows about who is welcome, and what the protocol does not replace.
Patients who haven't tested.
The protocol begins after a confirmed positive stool antigen, urea breath, or biopsy result. Empirical use in untested patients is not appropriate — it confounds diagnosis and exposes the patient to risk without indication.
Active ulcer or gastric red flags.
Active gastric or duodenal ulcers, suspected or known gastric malignancy, severe atrophic gastritis, unexplained weight loss, GI bleeding, or persistent vomiting require specialist evaluation first. The protocol is not the appropriate setting.
Patients who prefer to begin with a supplement protocol before pursuing antibiotic therapy are welcome — the physician consultation exists to ensure clinical appropriateness for your specific situation, not to require a specific treatment path.
What this protocol does not replace: a positive H. pylori test result, physician involvement, or confirmed eradication testing after treatment.
The Welyon Protocol — coming soon.
Welyon is developing a branded supplement protocol built on this evidence architecture — standardised ingredient forms, third-party GMP certification, and enrolment in our pre-registered observational study. If you would like to be notified when it becomes available, join the waitlist below.
One email when the Protocol launches. Unsubscribe in one click. No partner sharing.
A few honest questions.
How is the protocol different from a standard antibiotic course?
It's additive in most cases, not alternative. The protocol layers five mechanistic targets — biofilm disruption, multi-pathway antimicrobial pressure, efflux pump inhibition, persister-population targeting, and mucosal repair — on top of, or in sequence with, the appropriate guideline-concordant antibiotic regimen. The clinician decides the configuration per patient.
Will my insurance cover it?
Coverage varies. The physician consultation is itemised with appropriate E/M codes and is reimbursable under many plans as a telehealth visit. The protocol components are not separately reimbursed under most plans; pricing is published transparently at the consultation. HSA / FSA eligibility applies for the consultation in most cases.
What are the success rates?
Outcomes data is being collected through the pre-registered observational study. Until that data is published — anticipated 2026 — Welyon does not publish success-rate claims. Mechanistic justification, prior literature on each individual pathway, and the consultation's discussion of probability per case substitute for headline percentages.
Is the protocol the same for everyone?
No. The five-mechanism design is the template; the actual configuration is tailored by the consulting physician based on case history, prior eradication attempts, local antibiotic resistance patterns, contraindications, and the condition from the investigation series — if any — that prompted the workup.
What does the consultation cost?
Published transparently when waitlist opens. No surprise pricing, no membership fee, no recurring charge. The consultation is a one-time clinical visit; protocol components are priced separately and reviewed in full before initiation.
Can my own physician supervise the protocol?
Yes — co-management is supported. If your primary care, gastroenterology, or specialist physician prefers to supervise the protocol directly, Welyon provides the clinical protocol document and the relevant condition-specific guide. The practitioner page has the referral and co-management workflows.
FDA disclaimer
These statements have not been evaluated by the Food and Drug Administration. The Foundation Protocol is a clinical care pathway delivered through licensed physicians. The information on this page is for educational purposes and is not intended to diagnose, treat, cure, or prevent any disease. Clinical decisions belong to a licensed physician who can assess your specific case. Engagement with the protocol begins with a physician consultation; engagement is not initiated by visiting this page or joining the waitlist.
Commercial interest disclosure
Welyon operates the Foundation Protocol commercially. The consulting physicians are independent licensed clinicians contracted on a per-consultation basis; their clinical judgement — including the decision not to initiate the protocol — is independent of Welyon's commercial interest. The pre-registered observational study is conducted under independent IRB oversight; its findings, favourable or unfavourable, are reported.